Showing results (311-320 of 673) with videos related to
Sort By:
Pageof 68
HIV Clinical Trials|April 3, 2003
Morphologic alterations in HIV-infected people with lipodystrophy are associated with good adherence to HAARTGiovanni Guaraldi, Rita Murri, Gabriella Orlando, et al.HIV Clinical Trials|April 3, 2003
Effect of protease inhibitor-based highly active antiretroviral therapy on survival in HIV-associated advanced Kaposi's sarcoma patients treated with chemotherapyHeather Leitch, Marc Trudeau, Jean-Pierre RoutyHIV Clinical Trials|April 3, 2003
Reservoirs, sanctuaries, and residual disease: the hiding spots of HIV-1Roger J PomerantzHIV Clinical Trials|October 31, 2002
Simpler regimens may enhance adherence to antiretrovirals in HIV-infected patientsFranco Maggiolo, Diego Ripamonti, Claudio Arici, et al.HIV Clinical Trials|October 31, 2002
Infection with retroviruses other than HIV-1 in Spain: a retrospective analysis for HIV-2, HTLV-I, and/or HTLV-IICarlos Toro, Vincent Soriano, Concepción Tuset, et al.HIV Clinical Trials|October 31, 2002
Resistance to antiretroviral agents in individuals with HIV-1 non-B subtypesAfrica Holguín, Vincent SorianoHIV Clinical Trials|October 24, 2001
Evaluation of an efavirenz-containing regimen: an open-label, multicenter studyM Hartmann, A Rump, J Brust, et al.HIV Clinical Trials|February 11, 2003
Lipid changes in patients initiating efavirenz- and indinavir-based antiretroviral regimensKaren T Tashima, Linda Bausserman, Elizabeth N Alt, et al.HIV Clinical Trials|December 26, 2002
Intracellular concentration of protease inhibitors in HIV-1-infected patients: correlation with MDR-1 gene expression and low dose of ritonavirS Chaillou, J Durant, R Garraffo, et al.HIV Clinical Trials|August 21, 2002
Matrix metalloproteinase-9 and tissue inhibitors of matrix metalloproteinase-1 in plasma of patients co-infected with HCV and HIVClaudio M Mastroianni, Grazia M Liuzzi, Gabriella D'Ettorre, et al.Pageof 68